Ovarian clear cell carcinoma (OCCC) is the most refractory subtype of ovarian cancer and more prevalent in Japanese than Caucasians (25% and 5% of all ovarian cancer, respectively). The aim of this study is to discover the genomic alterations that may cause OCCC and effective molecular targets for chemotherapy. Paired genomic DNAs of 48 OCCC tissues and corresponding noncancerous tissues were extracted from formalin-fixed, paraffin embedded specimens collected between 2007 and 2015 at Tohoku University Hospital. All specimens underwent exome sequencing and the somatic genetic alterations were identified. We divided the cases into three clusters based on the mutation spectra. Clinical characteristics such as age of onset and endometriosis are similar among the clusters but one cluster shows mutations related to APOBEC activation, indicating its contribution to subset of OCCC cases. There are three hypermutated cases (showing 12-fold or higher somatic mutations than the other 45 cases) and they have germline and somatic mismatch repair gene alterations. The frequently mutated genes are ARID1A (66.7%), PIK3CA (50%), PPP2R1A (18.8%), and KRAS (16.7%). Somatic mutations important for selection of chemotherapeutic agents, such as BRAF, ERBB2, PDGFRB, PGR, and KRAS are found in 27.1% of OCCC cases, indicating clinical importance of exome analysis for OCCC. Our study suggests that the genetic instability caused by either mismatch repair defect or activation of APOBEC play critical roles in OCCC carcinogenesis. Mutation spectra analyses reveal that APOBEC activation may contribute to the carcinogenesis of some OCCC cases. In addition, three cases show hypermutability in OCCC and one case has germline deleterious mutation in the MSH6 gene, suggesting the involvement of Lynch syndrome in OCCC. Finally, our study shows the clinical implications of exome analysis of OCCC as 27.1% of the cases showed somatic mutations important for drug selection.
regimens (platinum and taxane) among EOC, and the median survival time of stage III/IV OCCC is significantly lower than that of HGS. 10 The JGOG3017/GCIG Trial that compared irinotecan and cisplatin with paclitaxel plus carboplatin in OCCC patients showed no difference in either progression free survival or overall survival. 11 The discovery of effective molecular target medicines for OCCC is necessary to improve the prognosis of the disease.
Molecular characterization of solid tumors with whole genome or exome sequencing has provided important insights in cancer biology.
Somatic mutations found in cancers may suggest personalized treatments for patients. For example, lung adenocarcinoma bearing EML4-ALK fusion gene is quite sensitive to specific ALK inhibitor such as crizotinib. 12 Similarly, Watanabe et al. 13 reported that remarkable tumor regression was induced by Vemurafenib to congenital anaplastic astrocytoma bearing the BRAF V600E mutation. This finding indicates that use of appropriate targeting agents can induce dramatic reduction of the tumor with corresponding driver mutations and such appropriate targets may be found with massive parallel sequencing of the patients' tumor genomic DNAs. Therefore, whole exome sequencing of cancers will be a powerful tool for the personalized selection of chemotherapeutic agents.
Previous studies revealed that ARID1A and PIK3CA are frequently mutated in OCCC, 46-57% and 40%, respectively. 14, 15 These studies analyzed mainly Caucasian samples and the pattern of mutated genes in OCCC may be different from East Asians. The aim of this study was to identify genomic alterations that may cause OCCC in Japanese and effective molecular targets for chemotherapy. We extracted 48 pairs of genomic DNAs from formalin fixed paraffin embedded (FFPE) OCCC and surrounding (matched) noncancerous FFPE tissue specimens as negative control for exome analysis, minimalizing the C to T artifacts. 16 Mutation spectra analyses reveal that APOBEC activation may contribute to the carcinogenesis of some OCCC cases. In addition, three cases show hypermutability in OCCC and one case has germline deleterious mutation in the MSH6 gene, suggesting the involvement of Lynch syndrome in OCCC. Finally, our study shows the clinical implications of exome analysis of OCCC as 27.1% of the cases showed somatic mutations important for drug selection.
| M A TE RI A L S A ND M E TH ODS

| Patient samples
The study was approved by the ethical committee of the Tohoku University School of Medicine. We selected 48 OCCC specimens that were chemotherapy or radiotherapy naïve from the collection of the Tohoku University Hospital between 2007 and 2015. The clinical information of patients is shown in Table 1 . Chemoresistant was defined as disease progression in computed tomography imaging during or within 6 months of primary therapy.
| DNA preparation
Surgically resected tumor specimens and corresponding noncancerous tissue were fixed in 10% formalin for 24-48 h and embedded in paraffin. Genomic DNA was extracted from FFPE specimens (Supporting Information Figure S1 ). Tissue sections were stained with hematoxylin and eosin (HE) and reviewed by a pathologist to confirm the area of OCCC lesions. OCCC and noncancerous areas were separately dissected from tissue sections (1-10 pieces, each 10 mm thickness) using a razor blade, and genomic DNA was extracted with a GeneRead DNA FFPE Kit (Qiagen, Germany) following the manufacturer's instructions.
All samples were compared to a matching normal DNA for exome analysis. The DNA quality was evaluated by electrophoresis. We measured concentrations of the double stranded nucleic acids as DNA with a Qubit 2.0 Fluorometer (Thermo Fisher Scientific, Waltham, MA).
| Library preparation for exome capture
For library preparation, 1 lg of genomic DNA from each sample was sheared to 150-200 bp fragments using a Covaris S220 instrument (Covaris, Woburn, MA). Each DNA library was prepared with SureSelectXT Reagents (Agilent Technologies, Santa Clara, CA) according to the manufacturer's instructions using a Bravo Automated Liquid Handling Platform (Agilent Technologies). Adaptor-ligated genomic DNA fragments were purified and eluted in 30 mL of nuclease-free water, and 15 mL of adaptor-ligated DNA was then amplified by 10 cycles of PCR using Herculase II Fusion DNA Polymerase (Agilent Technologies) according to the manufacturer's instructions. The amplified library was purified using AMPure XP reagent (Beckman Coulter, Brea, CA) and eluted in 30 mL of nuclease-free water.
| Exon capture
Precapture library DNA was hybridized to exon capture probes using the SureSelectXT Target Enrichment System (Agilent Technologies) according to the manufacturer's instructions. A total of 750 ng of library DNA was subjected to exon capture with Human All Exome V6 capture probe (Agilent). The probe-hybridized DNA was further amplified by polymerase chain reaction (PCR) using Herculase II Fusion DNA Polymerase (Agilent Technologies) and Index PCR Primer containing an 8-bp index sequence. The thermal cycling protocol was initial denaturation at 988C for 2 min followed by 12 cycles at 988C for 30 s, 578C for and Tohoku Medical Megabank Organization (ToMMo) 1KJPN, 21 to determine correspondence to the existing entries. Functional prediction scores including Mutation tester were estimated using dbNSFP version 30. 22 We also eliminated variants found in the error-prone genomic regions identified by two studies, 23, 24 for the analyses of correlation between gene mutation and clinical features (Supporting Information Table S7 ). This filtering caused the reduction of frequently mutated and clinical relevant genes in Supporting Information 
| Statistical analyses
Statistical analyses were performed using R software package version 3.3.1. 25 Correlations between clinical features and genetic variants were evaluated by Pearson's correlation test and Fisher's exact test.
Transition (Ts)/transversion (Tv) ratio, nonsynonymous single nucleotide variant (SNV)/synonymous SNV ratio and frameshift indels/ nonframeshift indels ratio were evaluated by Wilcoxon rank sum test.
Hierarchical clustering analysis for mutation spectra was performed using Figure 1 shows the cluster analyses of the spectra of 6 possible substitutions in OCCCs, and we selected 3 major clusters for further analyses (clusters A, B, and C: Figure 1A ,B).
Clusters A, B, and C consist of 21, 9, and 18 cases, respectively.
Clinical characteristics such as age of onset, endometriosis, and deep vein thrombosis are similar among the clusters. However, these three clusters show some distinct mutational patterns. For example, cluster A predominantly shows C to T transition, that is a characteristics of somatic mutations in most of cancer types, 27 but also known to be related to FFPE fixation. 16 The cluster B contains more C to G transition events (23.6%) compared with other clusters (cluster A: 9.4% and cluster C: 8.0%, Figure 1 ). Cluster C was enriched for T to A Table S2 .
APOBEC-related mutations 27, 28 are TCN to TKN or NGA to NMA (K@T or G and M@A or C in IUPAC nucleotide code). We classified the mutations based on the franking nucleotides of mutated ones and counted APOBEC related mutations ( Table 2 ). The cluster B shows 2.3-2.7 times more APOBEC related mutations (Table 2 ) and this difference is statistically significant (P 5 .001, Student's t test). This suggests that the activation of APOBEC is associated with the carcinogenesis in the cases of this cluster.
| Contribution of mismatch repair pathway in OCCC carcinogenesis
We identified three somatic hypermutated cases (Supporting Information Table S3 ). These three cases have 1,060 (811-1,549) SNVs on averages, which is a 12-fold higher mutation rate than the other 45
cases. To characterize somatic mutation signatures of the three cases, the Ts/Tv ratio, nonsynonymous SNV/synonymous SNV ratio and frameshift indels/nonframeshift indels ratio were compared with those of the 48 cases (Figure 2 ; Supporting Information Table S4 ). The Ts/Tv and nonsynonymous/synonymous SNVs ratios were similar between the three cases and others ( Figure 2 ; Supporting Information Table S4 ).
The frameshift indels/nonframeshift indels ratio was 8.1-fold higher in hypermutated cases than in others (P 5 .006, Wilcox rank sum test).
The elevated number of frameshift indels suggests that the hypermu- 
| Chromatin remodeling and PI3K pathways are major targets in OCCC carcinogenesis
To investigate the functional feature of the mutated genes in OCCC, we annotated the somatic mutations in our exome data with ANNO-VAR and mutations in the cancer gene census in COSMIC database were extracted (Figure 3 ). The most frequently mutated gene was Another novel mutated gene in OCCC is BUB1B in three cases.
The BUB1B functions at the mitotic spindle check point and it is frequently mutated in several types of cancers such as colorectal cancer and glioblastoma. 35 Other checkpoint-related genes such as TP53 and ATM were also mutated in a small fraction of OCCC cases.
| Several OCCC cases have potential chemotherapeutic target mutations
Traditionally, chemotherapy for ovarian cancer is designed as a single disease although its origins vary. A large part of OCCC cases is resistant to conventional chemotherapy, but it may be sensitive to molecular targeted drugs if the tumor renders mutations corresponding to specific chemotherapeutic agents.
Next generation sequence-based clinical cancer gene testing can uncover the driver mutations of the cancers, 36 and a proper molecular | 55 targeted therapy can be selected. As shown in Table 3 , BRAF, ERBB2, PDGFRB and PGR mutation were seen in five samples. These tumors have possibility to be used molecular target drugs indicating in Table 3 .
Conversely, KRAS mutation, which is an exclusion criterion for tyrosine kinase inhibitors, was discovered in eight cases. In total, 27.1% of the cases showed somatic mutations that have clinical implications, suggesting the clinical value of the exome analysis of OCCC.
| D I SCUSSION
The present study elucidates mutations in OCCC through whole exome analyses. The mutation spectra of the OCCC are utilized to classify the cases and one cluster shows characteristics of APOBEC activation. From the mutation spectra analysis, some of the cases were suspected to show dominantly affected APOBEC carcinogenesis. APOBEC carcinogenesis contributes to accumulation of "C to G" change in a TpC context. 28 Interestingly, activation of APOBEC is reported to increase PIK3CA helical domain mutations in multiple cancers including endometrial cancer. 40 In our case series, a large number of OCCCs harbored PIK3CA mutations. The number of PIK3CA helical domain mutationpositive cases in the Cluster B is four out of nine and that in Cluster A and C is 6 out of 39, respectively. Although it is not significant (P 5 .075, Fisher's exact test), we think our data partially support the previous observation by Henderson et al. 40 Intriguingly, Wang et al. 41 reported that 26% of OCCC manifested APOBEC signature and the frequency is similar to that of our collection (9/48). They also suggested that the mutated gene spectra of OCCC (frequent ARID1A and PIK3CA mutations) is not related to APOBEC signature. 41 However, the prevalence of PIK3CA mutations in APOBEC associated or unassociated OCCC in the study by Wang et al.
(7/9 and 11/26, respectively) are similar to that of our collection (6/9 and 18/39, respectively). Because Wang et al., and our studies are independent, we summed up the two data and this metadata show statistical significance (P 5 .034, Fisher's exact test), suggesting the contribution of APOBEC activation to the PIK3CA mutations in OCCC.
There are three hypermutated cases in our collection (showing 12-fold or higher somatic mutations than the other 45 cases), suggesting that these three cases have MMR defects. We examined germline variants in MMR genes in these cases and summarized the data in Supporting Information The most common somatic genetic alterations in OCCC are ARID1A, PIK3CA, PPP2R1A and KRAS. As previously reported, cooccurrence of ARID1A and PIK3CA was significantly high. 14 The two mutations are more prevalent in our collection, suggesting the fluctuation of histopathological diagnosis between serous ovarian cancers and OCCC. 44 One report showed that ARID1A inactivation and concurrent activation of PIK3CA induces OCCC formation in mice. 45 Loss of ARID1A and activation of PIK3CA would be a quite major course for carcinogenesis in OCCC. In this study, the SMARCA4 and ARID1B chromatin remodeling factors are also mutated. KRAS and PIK3R1, members 48 Nivolumab is an antiprogrammed death-1 (PD-1)
antibody that blocks PD-1 signaling. The PD-1 antibody inhibits the immune signal receptor expressed in T cells and regulates antitumor immunity. Nivolumab induced complete recession to 1 of two cases of platinum-resistant OCCCs. 49 Recently, targeted chemotherapeutic agents for ARID1A-mutated OCCC tumors by inducing synthetic lethality are developed. EZH2 inhibition caused the regression of ARID1A-mutated OCCC tumors by inhibiting PI3K-AKT pathway. 50 In addition, a tyrosine-kinase inhibitor dasatinib caused G1-S cell cycle arrest and consequently, regression of ARID1A-mutated OCCC tumors. 51 These studies show the clinical implication of these chemotherapeutic agents in ARID1A mutated OCCC cases. Considering the variety of the affected pathways in OCCC, whole exome analysis will contribute the choice of molecular targeted chemotherapeutic agents for OCCC.
| C ONC LUSI ON S
The present study elucidated the feature of mutations in OCCC through whole exome analyses. The mutation spectra of OCCC indicated that the contribution of APOBEC activation in OCCC carcinogenesis. In addition, three cases show a significant number of somatic mutations and further analysis indicates that the three cases have germline defects in the MMR pathway, suggesting that the defects in MMR pathway plays important roles in OCCC carcinogenesis. The most common somatic genetic alterations in OCCC are ARID1A, PIK3CA, PPP2R1A, and KRAS. As previously reported, co-occurrence of ARID1A and PIK3CA is significantly high. In our collection, however, these two mutations are more prevalent. One fourth of the cases showed somatic mutations that have clinical implications. Our study shows the importance of whole exome analyses of cancer tissue in both understanding of carcinogenesis and clinical practice.
